IBM and Nvidia move quantum processors into supercomputing workflows
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
Quantum / NEWS BRIEF
The new co-design environment colocates IBM Nighthawk processors with Oak Ridge's AMD-powered Umbra system so researchers can test low-latency quantum and classical error-correction workflows.
IBM, the Department of Energy-funded Quantum Science Center at Oak Ridge National Laboratory and AMD have deployed a quantum-error-correction co-design platform at IBM's Poughkeepsie site. It pairs IBM Nighthawk r2 processors, including a 120-qubit system, with Oak Ridge's Umbra high-performance system using AMD Instinct MI355X GPUs and fifth-generation EPYC CPUs. Reuters independently confirmed the launch and the principal hardware configuration.
Quantum error correction depends on classical decoders that interpret repeated qubit checks quickly enough to inform the next operations. Colocating the GPU and CPU resources with the quantum processors is intended to reduce handoff delays and let researchers test decoding, orchestration and hybrid algorithms without assembling separate infrastructure. IBM says the environment will also connect with the Oak Ridge Leadership Computing Facility.
The partners connect the work to a Department of Energy target of 100 logical qubits performing 100,000 difficult operations by late 2028. IBM reports experiments reaching 70 logical qubits and 438 such operations, leaving roughly a 230-fold operation-count gap. The new infrastructure may accelerate experiments, but it does not itself demonstrate fault tolerance, a new logical-error record or a scientifically useful quantum computation.
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
OpenAI has released healthcare-focused computer-use capabilities across its API and clinical products, with configurable approvals, audit logs and new performance results that remain provider-reported.